MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
OPK stock logo

OPK

OPKO Health, Inc.

$1.42
-0.03
 (-2.07%)
Exchange:  NASDAQ
Market Cap:  1.072B
Shares Outstanding:  5.094M
Delayed data
Calculate OPK Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Phillip Frost
Full Time Employees:  2997
Address: 
4400 Biscayne Boulevard
Miami
FL
33137
US
Website:  https://www.opko.com
OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company’s Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrument system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, produces and sells items primarily within the generics market, and handles the import, marketing, distribution, and sales of pharmaceutical products across various therapeutic areas, including cardiovascular conditions, vaccines, antibiotics, gastro-intestinal ailments, and hormone-related treatments, among others. Its pharmaceutical operations are further bolstered by platforms situated in Ireland, Chile, Spain, and Mexico. Founded in 1991, OPKO Health, Inc. maintains its corporate headquarters in Miami, Florida.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/04/30 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue863,495713,142606,879
Gross Profit318,127311,033128,050
EBITDA-65,516135,279-41,304
Operating Income-157,021-152,065-218,985
Net Income-188,863-53,224-225,680

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets2,011,6982,200,2121,931,944
Total Liabilities622,479834,764517,308
Total Stockholders Equity1,389,2191,365,4481,267,959
Total Debt326,564504,444412,235
Cash and Cash Equivalents95,881431,936369,074

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-28,197-183,489-178,542
Capital Expenditure-16,275-25,010-12,278
Free Cash Flow-44,472-208,499-190,820
Net Income-188,863-53,224-225,680
Net Change in Cash-57,310349,734-62,873

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)666,899.619Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)706,528.523Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)690,050Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-45,023.491Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-42,498.141Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-43,973.398Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)-61,956.099Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)-57,469.868Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)-60,090.631Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)237,072.462Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)251,159.922Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)245,302.063Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)-0.080Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)-0.080Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)-0.080Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
713.142M  ?P/S
 (TTM)
: 
1.87
?Net Income
 (TTM)
: 
-53224000  ?P/E
 (TTM)
: 
-5.13
?Enterprise Value
 (TTM)
: 
1.142B  ?EV/FCF
 (TTM)
: 
-6.56
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.17  ?ROIC
 (TTM)
: 
-0.11
?Net Debt
 (TTM)
: 
72.508M  ?Debt/Equity
 (TTM)
: 
0.33
?P/B
 (TTM)
: 
0.91  ?Current Ratio
 (TTM)
: 
3.61

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about OPK valuation

Is OPKO Health, Inc. (OPK) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for OPKO Health, Inc. (OPK) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is OPK a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether OPK trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is OPK’s P/E ratio?

You can see OPK’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for OPK?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is OPK a good long-term investment?

Whether OPK fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

OPK

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-2.07
MARKETSnap

Trading Metrics:

Open: 1.45   Previous Close: 1.45
Day Low: 1.42   Day High: 1.48
Year Low: 0.98   Year High: 1.6
Price Avg 50: 1.23   Price Avg 200: 1.31
Volume: 1.743M   Average Volume: 2.581M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Here's Why You Should Retain OPK Stock in Your Portfolio for Now
21-05-2026 13:26
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health (OPK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
28-04-2026 20:01
OPKO Health (OPK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates
28-04-2026 20:00
OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates
Here's Why You Should Hold OPK Stock in Your Portfolio for Now
23-04-2026 13:11
Here's Why You Should Hold OPK Stock in Your Portfolio for Now
OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts
27-02-2026 13:50
OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts
OPKO Health, Inc. (OPK) Q4 2025 Earnings Call Transcript
26-02-2026 20:57
OPKO Health, Inc. (OPK) Q4 2025 Earnings Call Transcript

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read